In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Richard J. Gilbertson, MD, PhD
Member, St. Jude Faculty
Director, Molecular Clinical Trials Core
Co-Leader, Neurobiology & Brain Tumor Program
Departments
Developmental Neurobiology
Oncology
Contact Information
Richard Gilbertson, MD, PhD
Developmental Neurobiology
Room D2006G
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: richard.gilbertson@stjude.org
Phone: (901) 595-3913
FAX: (901) 595-2270
Research Interests
The principal aim of my research is to reduce the morbidity and mortality of children with central nervous system tumors through improved understanding of tumor biology. We hope to achieve this goal by:
- Conducting extensive genomic analyses of brain tumors to identify cancer causing genetic abnormalities.
- Integrating studies of genetic and cell signal alterations in cancers with studies of normal progenitor cells to determine the cellular and molecular origins of tumors.
- Translating knowledge of tumor biology into effective new cures for brain tumors through pre-clinical and early clinical trials of molecular targeted therapies.
Selected Publications
Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, Mcleod J, Scherer SW, Rao JS, Eberhart CG, Grajkowska W, Gillespie Y, Lach B, Grundy R, Pollack IF, Hamilton RL, Van Meter T, Carlotti CG, Boop F, Bigner D, Gilbertson RJ, Rutka JT, Taylor MD. Multiple Recurrent Genetic Events Converge on Control of Histone Lysine Methylation in Medulloblastoma. Nature Genet 41: 465 – 472, 2009.
Uziel T, Karginov FV, Xie S, Parker JS, Wang Y-D, Gajjar A, He L, Ellison DW, Gilbertson RJ, Hannon G, Roussel MF. The mir-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. PNAS 106: 2812-7, 2009.
Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457:603-7, 2009. (Editors Choice in Nature Rep Stem Cells; Research Highlight in Nature Rev Cancer)
Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Ann Rev Pathol 3:341-365, 2008.
Gilbertson RJ, Rich JN. Making a tumor’s bed: the glioblastoma stem cell niche. Nat Rev Cancer 7:733-6, 2007.
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber W, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A Perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahem V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Excellent outcomes after risk-adapted craniospinal radiation therapy followed by a short period of high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma: results of a prospective multicenter trial (SJMB-96). Lancet Oncol 7: 813-820, 2006.
Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies subgroups of medulloblastoma that are enriched for specific genetic abnormalities. J Clin Oncol 24: 1924-1931, 2006. Supplemental data
Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdelano S, Dalton J, Board J, MacDonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ. Radial Glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323-335, 2005. Supplemental data
Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 5: 209-18, 2004.
Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon P, Wallace D, Lau C, Chintagumpala M, Ashley D, Kellie S, Kun L, Gilbertson R. Clinical, histopathological and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-93, 2004.
Last update: June 2009
